Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Janux Therapeutics Inc’s stock clocked out at $22.84, down -0.61% from its previous closing price of $22.98. In other words, the price has decreased by -$0.61 from its previous closing price. On the day, 0.84 million shares were traded. JANX stock price reached its highest trading level at $23.7 during the session, while it also had its lowest trading level at $22.8.
Ratios:
To gain a deeper understanding of JANX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 47.03 and its Current Ratio is at 47.03. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Barclays on September 17, 2025, initiated with a Overweight rating and assigned the stock a target price of $47.
On September 10, 2025, Truist started tracking the stock assigning a Buy rating and target price of $100.
On September 10, 2025, Stifel started tracking the stock assigning a Buy rating and target price of $45.Stifel initiated its Buy rating on September 10, 2025, with a $45 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 01 ’25 when Meyer Andrew Hollman sold 3,333 shares for $32.03 per share. The transaction valued at 106,745 led to the insider holds 82,139 shares of the business.
ANDREW MEYER bought 3,333 shares of JANX for $110,656 on May 01 ’25. On Apr 21 ’25, another insider, Meyer Andrew Hollman, who serves as the Chief Business Officer of the company, sold 3,334 shares for $30.00 each. As a result, the insider received 100,020 and left with 82,139 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JANX now has a Market Capitalization of 1372545408 and an Enterprise Value of 398724416. For the stock, the TTM Price-to-Sale (P/S) ratio is 3119.43 while its Price-to-Book (P/B) ratio in mrq is 1.37. Its current Enterprise Value per Revenue stands at 908.256 whereas that against EBITDA is -2.792.
Stock Price History:
The Beta on a monthly basis for JANX is 2.81, which has changed by -0.5100815 over the last 52 weeks, in comparison to a change of 0.15535986 over the same period for the S&P500. Over the past 52 weeks, JANX has reached a high of $71.71, while it has fallen to a 52-week low of $21.97. The 50-Day Moving Average of the stock is -6.18%, while the 200-Day Moving Average is calculated to be -28.85%.
Shares Statistics:
It appears that JANX traded 785.81K shares on average per day over the past three months and 755600 shares per day over the past ten days. A total of 59.30M shares are outstanding, with a floating share count of 54.08M. Insiders hold about 10.00% of the company’s shares, while institutions hold 106.15% stake in the company. Shares short for JANX as of 1756425600 were 8048523 with a Short Ratio of 10.24, compared to 1753920000 on 8733357. Therefore, it implies a Short% of Shares Outstanding of 8048523 and a Short% of Float of 19.24.
Earnings Estimates
The market rating of Janux Therapeutics Inc (JANX) is currently shaped by the ongoing analysis conducted by 12.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.71, with high estimates of -$0.38 and low estimates of -$1.22.
Analysts are recommending an EPS of between -$1.42 and -$3.19 for the fiscal current year, implying an average EPS of -$2.23. EPS for the following year is -$3.11, with 13.0 analysts recommending between -$1.87 and -$5.5.
